RhumbLine Advisers
PGNX

RhumbLine Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

RhumbLine Advisers’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-279,220
Closed -$1.06M – 3171
2020
Q1 		$1.06M Sell
279,220
-83
-0% -$358 ﹤0.01% 1856
2019
Q4 		$1.42M Buy
279,303
+18,508
+7% +$97.9K ﹤0.01% 1934
2019
Q3 		$1.32M Buy
260,795
+3,467
+1% +$17.3K ﹤0.01% 1917
2019
Q2 		$1.59M Buy
257,328
+16,567
+7% +$79.9K ﹤0.01% 1862
2019
Q1 		$1.12M Sell
240,761
-1,973
-0.8% -$8.93K ﹤0.01% 1985
2018
Q4 		$1.02M Buy
242,734
+45,483
+23% +$232K ﹤0.01% 2000
2018
Q3 		$1.24M Buy
197,251
+17,537
+10% +$135K ﹤0.01% 1905
2018
Q2 		$1.45M Buy
179,714
+15,080
+9% +$115K ﹤0.01% 1847
2018
Q1 		$1.23M Buy
164,634
+5,074
+3% +$33.7K ﹤0.01% 1844
2017
Q4 		$949K Buy
159,560
+20,853
+15% +$127K ﹤0.01% 1972
2017
Q3 		$1.02M Buy
138,707
+2,970
+2% +$18.9K ﹤0.01% 1963
2017
Q2 		$922K Sell
135,737
-32
-0% -$236 ﹤0.01% 1986
2017
Q1 		$1.28M Buy
135,769
+58,042
+75% +$579K ﹤0.01% 1804
2016
Q4 		$672K Buy
77,727
+4,204
+6% +$31.1K ﹤0.01% 2069
2016
Q3 		$465K Sell
73,523
-7,465
-9% -$45.1K ﹤0.01% 2248
2016
Q2 		$342K Buy
80,988
+11,223
+16% +$54.2K ﹤0.01% 2451
2016
Q1 		$304K Buy
69,765
+635
+0.9% +$2.83K ﹤0.01% 2523
2015
Q4 		$424K Buy
69,130
+4,405
+7% +$28.9K ﹤0.01% 2350
2015
Q3 		$370K Buy
64,725
+2,322
+4% +$17.8K ﹤0.01% 2424
2015
Q2 		$466K Sell
62,403
-26,890
-30% -$163K ﹤0.01% 2382
2015
Q1 		$534K Buy
89,293
+2,800
+3% +$17.6K ﹤0.01% 2268
2014
Q4 		$654K Buy
86,493
+6,700
+8% +$40.1K ﹤0.01% 2093
2014
Q3 		$414K Hold
79,793
– – ﹤0.01% 2331
2014
Q2 		$344K Buy
79,793
+27,914
+54% +$107K ﹤0.01% 2507
2014
Q1 		$212K Sell
51,879
-1,910
-4% -$9.77K ﹤0.01% 2739
2013
Q4 		$287K Hold
53,789
– – ﹤0.01% 2609
2013
Q3 		$271K Buy
53,789
+72
+0.1% +$391 ﹤0.01% 2602
2013
Q2 		$240K Buy
+53,717
New +$241K ﹤0.01% 2843

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

RhumbLine Advisers's PGNX Position: Q2 2020 in Review

RhumbLine Advisers sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 279,220 shares — an estimated $1.06M sold.

RhumbLine Advisers first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $1.59M in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • RhumbLine Advisers reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 279,220 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1.06M.
  • RhumbLine Advisers first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • RhumbLine Advisers's Progenics Pharmaceuticals Inc position peaked at $1.59M in Q2 2019.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.